BeOne Medicines Ltd. (ONC) stock
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/301935% above fair value
$416.54+0.58 (+0.14%)
Close on Nov 13, 2026Market cap $47.36BP/E 53.4Yield –
BeOne Medicines ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BeOne Medicines's ebitda for the twelve months ending Sep 30, 2026 was $1.36B, up 300.8% year over year. For fiscal 2025 it was $588.82M. The highest annual figure on record is $588.82M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $588.82M | – |
| FY2024 | Dec 31, 2024 | -$396.44M | – |
| FY2023 | Dec 31, 2023 | -$1.12B | – |
| FY2022 | Dec 31, 2022 | -$1.72B | – |
| FY2021 | Dec 31, 2021 | -$1.39B | – |
| FY2020 | Dec 31, 2020 | -$1.63B | – |
| FY2019 | Dec 31, 2019 | -$941.27M | – |
| FY2018 | Dec 31, 2018 | -$695.38M | – |
| FY2017 | Dec 31, 2017 | -$93.70M | – |
| FY2016 | Dec 31, 2016 | -$115.15M | – |
| FY2015 | Dec 31, 2015 | -$55.20M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $479.61M | +139.3% |
| Q2 FY2026 | Jun 30, 2026 | $365.56M | +196.0% |
| Q1 FY2026 | Mar 31, 2026 | $291.05M | +562.9% |
| Q4 FY2025 | Dec 31, 2025 | $221.02M | – |
| Q3 FY2025 | Sep 30, 2025 | $200.40M | – |
| Q2 FY2025 | Jun 30, 2025 | $123.50M | – |
| Q1 FY2025 | Mar 31, 2025 | $43.91M | – |
| Q4 FY2024 | Dec 31, 2024 | -$29.18M | – |
| Q3 FY2024 | Sep 30, 2024 | -$48.97M | – |
| Q2 FY2024 | Jun 30, 2024 | -$82.23M | – |
| Q1 FY2024 | Mar 31, 2024 | -$236.06M | – |
| Q4 FY2023 | Dec 31, 2023 | -$359.98M | – |
| Q3 FY2023 | Sep 30, 2023 | -$112.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$296.38M | – |
| Q1 FY2023 | Mar 31, 2023 | -$351.25M | – |
| Q4 FY2022 | Dec 31, 2022 | -$450.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$422.16M | – |
| Q2 FY2022 | Jun 30, 2022 | -$423.94M | – |
| Q1 FY2022 | Mar 31, 2022 | -$426.69M | -634.7% |
| Q4 FY2021 | Dec 31, 2021 | -$558.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$450.15M | – |
| Q2 FY2021 | Jun 30, 2021 | -$463.31M | – |
| Q1 FY2021 | Mar 31, 2021 | $79.80M | – |
| Q4 FY2020 | Dec 31, 2020 | -$477.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$431.79M | – |
| Q2 FY2020 | Jun 30, 2020 | -$351.01M | – |
| Q1 FY2020 | Mar 31, 2020 | -$366.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$380.55M | – |
| Q3 FY2019 | Sep 30, 2019 | -$308.24M | – |
| Q2 FY2019 | Jun 30, 2019 | -$82.14M | – |
| Q1 FY2019 | Mar 31, 2019 | -$170.34M | – |
| Q4 FY2018 | Dec 31, 2018 | -$277.45M | – |
| Q3 FY2018 | Sep 30, 2018 | -$148.66M | -227.9% |
| Q2 FY2018 | Jun 30, 2018 | -$160.71M | – |
| Q1 FY2018 | Mar 31, 2018 | -$108.57M | – |
| Q4 FY2017 | Dec 31, 2017 | -$101.74M | – |
| Q3 FY2017 | Sep 30, 2017 | $116.21M | – |
| Q2 FY2017 | Jun 30, 2017 | -$57.48M | – |
| Q1 FY2017 | Mar 31, 2017 | -$50.68M | – |
| Q4 FY2016 | Dec 31, 2016 | -$36.80M | – |
See a number that looks wrong?